Imaging taxane-induced tumor apoptosis using PEGylated, 111In-labeled annexin V

被引:0
作者
Ke, S
Wen, XX
Wu, QP
Wallace, S
Charnsangavej, C
Stachowiak, AM
Stephens, CL
Abbruzzese, JL
Podoloff, DA
Li, C
机构
[1] Univ Texas, MD Anderson Canc Ctr, Div Diagnost Imaging, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
关键词
apoptosis; nuclear imaging; annexin V; paclitaxel; polyethylene glycol;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Tc-99m-Labeled annexin V has been used for the imaging of tumor apoptosis induced by chemotherapy. However, owing to the short half-life of annexin V, multiple injections of the radio-tracer are necessary to capture the peak apoptotic activity. In this study, we evaluated the imaging properties of an "'Inlabeled, long-circulating annexin V. Methods: Both polyethylene glycol (PEG) and the metal chelator diethylenetriaminepentaacetic acid (DTPA) were simultaneously introduced to annexin V or ovalbumin through the use of a heterofunctional PEG precursor. Imaging studies were performed in mice bearing subcutaneously inoculated human mammary MDA-MB-468 tumors. The mice were treated with POIY(L-glutamic acid)-paclitaxel, monoclonal antibody C225, or a combination Of POIY(L-glutamic acid)-paclitaxel and C225, followed by intraver injection of In-111-DTPA-PEG-annexin V. Images were acquired 48 h after the injection of the radiotracer. Autoradiography and TUNEL (terminal deoxynucleotidyltransferase-mediated dUTP nick-end labeling) staining were performed on adjacent tumor slices for the localization of apoptotic cells. The imaging properties of unPEGylated annexin V and PEGylated ovalbumin were also determined to permit assessment of the specificity of (111)InDTPA-PEG-annexin Results: Tumor apoptotic index 'increased from 1.67% +/- 0.31 % at baseline to 7.60% +/- 0.72% and 11.07% +/- 1.81%, respectively, 4 d after treatment with POIY(L-glutamic acid)-paclitaxel or combined POIY(L-glutamic acid)-paclitaxel and C225. Tumor uptake (percentage of injected dose per gram of tumor [%ID/g]) of PEGylated In-111-DTPA-PEG-annexin 4 d after treatment was significantly higher in tumors treated with POIY(L-glutamic acid)-paclitaxel (10.76 +/- 1.38 %ID/g; P = 0.001) and with combined POIY(L-glutamic acid)-paclitaxel and C225 (9.84 +/- 2.51 %ID/g; P = 0.029) than in nontreated tumors (6.14 +/- 0.67 %ID/g), resulting in enhanced visualization of treated tumors. In-111-DTPA-PEG-annexin V distributed into the central zone of tumors, whereas "'In-DTPAannexin V was largely confined to the tumor periphery. Furthermore, uptake of In-111-DTPA-PEG-annexin V by tumors correlated with apoptotic index (r = 0.87, P = 0.02). Increase in tumor uptake of the nonspecific PEGylated protein In-111-DTPA-PEG-ovalbumin was also observed after POIY(L-glutamic acid)paclitaxel treatment (55.6%), although this increase was lessthan that observed for In-111-DTPA-PEG-annexin V (96.7%). Conclusion: Increased uptake of and improved visualization with In-111-DTPA-PEG-annexin V in solid tumors after chemotherapy are mediated through both specific binding to apoptotic cells and nonspecific retention of macromolecular contrast agents in the tumors. In-111-Labeled, PEGylated annexin V may be used to assess tumor response to chemotherapy.
引用
收藏
页码:108 / 115
页数:8
相关论文
共 16 条
[1]  
Belhocine T, 2002, CLIN CANCER RES, V8, P2766
[2]  
Blankenberg F, 2002, CLIN CANCER RES, V8, P2757
[3]   In vivo detection and imaging of phosphatidylserine expression during programmed cell death [J].
Blankenberg, FG ;
Katsikis, PD ;
Tait, JF ;
Davis, RE ;
Naumovski, L ;
Ohtsuki, K ;
Kopiwoda, S ;
Abrams, MJ ;
Darkes, M ;
Robbins, RC ;
Maecker, HT ;
Strauss, HW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (11) :6349-6354
[4]   Apoptosis: The importance of nuclear medicine [J].
Blankenberg, FG ;
Tait, J ;
Ohtsuki, K ;
Strauss, HW .
NUCLEAR MEDICINE COMMUNICATIONS, 2000, 21 (03) :241-250
[5]   Therapeutic antibody fragments with prolonged in vivo half-lives [J].
Chapman, AP ;
Antoniw, P ;
Spitali, M ;
West, S ;
Stephens, S ;
King, DJ .
NATURE BIOTECHNOLOGY, 1999, 17 (08) :780-783
[6]  
FAN Z, 1993, CANCER RES, V53, P4322
[7]   THE CLINICAL EFFICACY OF POLY(ETHYLENE GLYCOL)-MODIFIED PROTEINS [J].
FUERTGES, F ;
ABUCHOWSKI, A .
JOURNAL OF CONTROLLED RELEASE, 1990, 11 (1-3) :139-148
[8]   Apoptosis - Gone but not forgotten [J].
Green, DR ;
Beere, HM .
NATURE, 2000, 405 (6782) :28-29
[9]  
Inoue K, 2000, CLIN CANCER RES, V6, P4874
[10]   Poly(L-glutamic acid) - anticancer drug conjugates [J].
Li, C .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (05) :695-713